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Summary
Cutaneous melanoma is the most deadly cutaneous neo-
plasm. In order to guide treatment decisions and follow-
up of melanoma patients, guidelines for the management of
melanoma in Switzerland were inaugurated in 2001 and re-
vised in 2006 and 2016. Recent data on surgical and medic-
al treatments from randomised trials necessitated modific-
ation of the treatment and follow-up recommendations.
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Introduction
The incidence of cutaneous melanoma is the highest in
Europe and still rising. Melanoma is responsible for most
deaths caused by skin malignancies. For these reasons,
treatment guidelines have been published in 2001 and were
revised in the versions of 2006 and 2011 [1, 2], in order to
provide reasonable practical recommendations for all phys-
icians (general practitioners, dermatologists, surgeons, on-
cologists and others) who encounter cutaneous melanoma
in their daily work [3]. The recommendations presented
here have been graded according to the amount of scientif-
ic evidence supporting them using the “Level of Evidence”
classification [4].
Levels of evidence:
IA Evidence from meta-analysis of randomised con-
trolled trials
IB Evidence from at least one randomised controlled tri-
al
IIA Evidence from at least one controlled study without
randomisation
IIB Evidence from at least one other type of quasi-experi-
mental study
III Evidence from nonexperimental descriptive studies,
such as comparative studies, correlation studies and
case-control studies
IV Evidence from expert committee reports or opinions
or clinical experience of respected authorities, or both
Grades of recommendations:
A Directly based on Level I evidence
B Directly based on Level II evidence or extrapolated
recommendations from Level I evidence
C Directly based on Level III evidence or extrapolated
recommendations from Level I or II evidence
D Directly based on Level IV evidence or extrapolated
recommendations from Level I, II, or III evidence
The purpose of these updated guidelines is to ensure the
adequate management and treatment of melanoma patients
in Switzerland. Patients with low-risk melanoma still tend
to be over-treated, whereas the therapy and follow-up pro-
cedures for patients with high-risk or metastasising melan-
oma are sometimes inadequate, especially if the patients
are managed outside centres of excellence. Drawing on
the combined expertise of a multidisciplinary team, the
guidelines reflect current international standards and the
state of the art [5]. Departure from these guidelines in spe-
cial clinical situations is at the discretion of the individual
physician.
There are several important differences between the Swiss
recommendations and other recommendations:
1. Based on daily experience, the quality of the sentinel
lymph node procedure (imaging, surgery and histolo-
gical evaluation of the node) is sometimes poor in
Switzerland. The guidelines therefore underline the
necessity to refer patients with intermediate risk to
specialised centres in order to assure adequate quality.
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 9
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
93
91
0 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
2. The best population for adjuvant interferon therapy
are patients with micrometastases and/or ulceration.
Pegylated interferon-alpha 2b injected weekly is pre-
ferred, based on its favourable pharmacology and its
easier use for patients, and is approved in Switzerland.
3. New approaches such as immune checkpoint inhibit-
ors and kinase inhibitors are approved first-line treat-
ment options. In order to improve our knowledge fur-
ther, clinical and translational research is essential.
Therefore, patients should be referred to centres that
are able to include patients in clinical trials and are
fulfilling strict quality assurance.
4. Positron emission tomography (PET) / computed
tomography (CT) scanning is covered by the Swiss
health insurers for melanoma follow up. Its role is re-
stricted to high-risk patients.
Clinical melanoma subtypes [6]
Superficial spreading melanoma (SSM) is the most com-
mon subtype (70%) and is characterised by an initial flat
phase that shows changes in size, shape or colour. SSM
may occur in young adults but the mean age is in the 40s.
More than 100 melanocytic naevi and multiple dysplastic
naevi are strong risk factors. SSM has been linked to inter-
mittent ultraviolet (UV) light exposure and sunburns, espe-
cially in adolescence and childhood.
Nodular melanoma (NM) accounts for about 15% of
melanomas overall, but for the majority of thick melano-
mas. It presents as a symmetrical, raised, firm, often uni-
formly coloured and frequently non-pigmented nodule that
is rapidly enlarging and becoming more raised. Bleeding
and crusting are common. NM occurs more often in older
people, particularly men, and is more commonly seen on
the head and neck than elsewhere.
SSM and NM often carry BRAF mutations.
Lentigo maligna (LM) and lentigo maligna melanoma
(LMM, the invasive form of LM) account for 10–15% of
melanomas. It has an initial flat phase that may be pro-
longed. It presents as an evolving pigmented macule and
has to be differentiated from seborrhoeic keratoses, solar
lentigines and pigmented actinic keratoses. LM has been
linked epidemiologically to large cumulative doses of UV
light, has a strong predilection for the head and neck, and
is more common in outdoor workers, in older people and in
association with solar damage and nonmelanoma skin can-
cer. Desmoplastic melanoma often arises in LMM.
Acral lentiginous melanoma (ALM) accounts for 1–3% of
melanomas and occurs on the acral skin of the palms and
soles including the nail apparatus. Importantly, melanomas
that appear relatively flat on the soles of the feet may have
significant depth histologically. Although the epidemi-
ology is not as well understood, this type of melanoma is at
least equally common in people with dark skin and has no
relationship with UV exposure.
Rare variants of melanoma. There are other, rare variants
of melanoma such as naevoid or acanthotic, amelanotic
melanomas and mucosal (e.g., oral cavity, sinus, oesophag-
us, rectum, vulva/vagina, etc.) which represent together not
more than 5% of all melanomas.
Diagnosis of melanoma
Skin examination for melanoma screening requires inspec-
tion of the entire body surface under good conditions (good
lighting). Dermoscopy is a noninvasive technique with a
hand-held magnifying device and immersion technique or
polarised light in order to render the stratum corneum trans-
lucent. This technique allows the visualisation of diagnost-
ic features of pigmented skin lesions that are not seen with
the naked eye and has been shown to improve diagnostic
accuracy significantly compared with naked eye examina-
tion in the hands of an experienced investigator (level of
evidence Ia).
Lesions that are different from the patient’s other lesions
(ugly duckling lesions) [7], lesions that have a history of
change (dynamic) or lesions with the dermoscopy criteria
of severe atypia or malignancy should be excised.
Fast growth and ulceration are important features of thick
melanomas including amelanotic melanoma.
Diagnosis should be based on a full thickness excisional
biopsy with a small side margin. Processing by an experi-
enced pathology institute is mandatory.
Staging
Physical examination with special attention to other suspi-
cious pigmented lesions, tumour satellites, in-transit meta-
stases, regional lymph node and systemic metastases is
mandatory.
In low-risk melanomas (tumour thickness <1 mm) no other
investigations are recommended. In higher stages imaging
as suggested in the follow-up section is recommended in
order to allow proper staging.
The improved version of the pTNM [8, 9] system (table 1)
is the classification system of choice.
Therapy
Surgical treatment of localised primary melanoma
Diagnosis should be based on a full thickness excisional
biopsy. Suspicious melanocytic lesions should be excised
completely, with a narrow clinical margin (level of eviden-
ce IV). The final diagnosis of melanoma is made histolo-
gically.
The histology report should follow the World Health Or-
ganization classification and include maximum thickness
in millimetres (Breslow), presence of ulceration, determin-
ation of mitotic rate in tumours <1 mm, presence and extent
of regression and clearance of the surgical margins [10].
The final surgical therapy should be carried out within 4
to 6 weeks following primary resection, leaving a safety
margin of 1–2 cm, depending on the thickness of the tu-
mour (table 2). Special locations, such as the face, may ne-
cessitate exceptions from the recommended safety margins
but micrographically controlled surgery should be used. In
these locations, radiotherapy might be considered as an al-
ternative treatment option for lentigo maligna melanoma
[11].
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Sentinel lymph node biopsy
In the past decade, sentinel lymph node biopsy (SLNB) has
become standard for staging cutaneous melanoma. The ac-
curacy and reliability of the method, and the status of the
sentinel lymph node (SLN) as the single most important
prognostic factor for tumour recurrence and survival of
melanoma patients has been proven beyond any reasonable
doubt (level of evidence IV) [12]. SLNB does not improve
overall survival [13]; however, there is general agreement
that it will help identify patients who might benefit from
further therapy, such as completion lymph node dissection
(CLND) and adjuvant interferon therapy, and will allow
their enrolment in adjuvant-therapy clinical trials [14].
SLNB should be discussed with and offered to all patients
with primary melanoma of Breslow thickness equal to or
greater than 1.0 mm and clinically normal regional lymph
nodes (determined by physical examination and/or ultra-
sound). In patients with a thickness between 0.7 and 1.0
mm, SLNB should be considered and discussed in healthy
patients with additional risk factors such as enhanced pro-
liferation or ulceration (pT1b) [15].
According to the current TNM classification and the UICC
[9] (International Union Against Cancer, Issue 7), lymph
node micrometastases have to be distinguished from isol-
ated tumour cells. Isolated tumour cells are single tumour
cells or small clusters of cells that are smaller than 0.2 mm,
can be detected with immunohistochemistry and are also
visible with conventional stains. Isolated tumour cells do
not have typical features of metastases such as proliferation
or stromal reactions.
The pathology report for the SLNB should clearly distin-
guish between isolated tumour cells and metastases. Meta-
stases are larger than 0.2 mm or, if smaller, show features
such as sinus contact, stromal reaction or proliferation. It is
essential to indicate the maximum diameter of the lymph
node metastasis or extranodal involvement. In contrast to
breast cancer, in melanoma SLNB micro- and macrometa-
stases are not histopathological terms, but correspond to
occult versus clinically apparent metastases. In order to
provide high-quality histopathological assessments the his-
tological diagnosis of melanoma should be confirmed by a
reference pathologist for quality reassurance [16].
Table 1: The 2009 staging system for cutaneous melanoma according to the American Joint Committee on Cancer and Union for International
Cancer Control [8, 9]. Reprint from: Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC
melanoma staging and classification. J Clin Oncol. 2009;27:6199–206, with permission from The American Society of Clinical Oncology.
Classification Thickness (mm) Ulceration status / mitoses
T
Tis NA NA
a: Without ulceration and mitosis <1/mm2T1 ≤1.00
b: With ulceration or mitoses ≥1/mm2
a: Without ulcerationT2 1.01–2.00
b: With ulceration
a: Without ulcerationT3 2.01–4.00
b: With ulceration
a: Without ulcerationT4 >4.00
b: With ulceration
N Number of metastatic nodes Nodal metastatic burden
N0 0 NA
a: Micrometastasis*N1 1
b: Macrometastasis†
a: Micrometastasis*
b: Macrometastasis†
N2 2–3
c: In-transit metastases / satellites without metastatic
nodes
N3 4+ metastatic nodes, or matted nodes, or in transit
Metastases/satellites with metastatic nodes
M Site Serum LDH
M0 No distant metastases NA
M1a Distant skin, subcutaneous, or nodal metastases Normal
M1b Lung metastases Normal
M1c All other visceral metastases Normal
Any distant metastasis Elevated
LDH = lactate dehydrogenase; NA = not applicable.
* Micrometastases are diagnosed after sentinel lymph node biopsy.
† Macrometastases are defined as clinically detectable nodal metastases confirmed pathologically.
Reprinted with permission. © 2009 American Society of Clinical Oncology. All rights reserved. Balch CM, et al. J Clin Oncol. 2009;27:6199–206
Table 2: Excision safety margins (I, A) for surgical treatment of primary melanoma (pT1–4NxM0) [2].
Tumour thickness (Breslow) Excision safety margin (cm)
Melanoma in situ (tumour thickness is not indicated) (pTisN0M0) 0.5
<2 mm (pT1–2N0M0) 1
>2 mm (pT3–4N0M0) 2
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The pathological investigation of the sentinel lymph node
is difficult and should be performed in institutes of patho-
logy with a high level of experience.
Completion lymph node dissection
Routine elective lymphadenectomy or irradiation to the re-
gional lymph nodes is not recommended (II, B).
Following the introduction of SLNB as standard of care
in the treatment regimen of cutaneous melanoma, comple-
tion lymph node dissection (CLND) was recommended,
according to the Augsburg Consensus guidelines [17], for
all patients with a positive SLNB. Thus, roughly 80% of
all patients who were sentinel-negative were spared elect-
ive lymph node dissection. Whereas SLNB is a minimally
invasive procedure with limited morbidity, CLND, much
like extended lymph node dissection (ELND), is associated
with considerable complication rates and socioeconomic
costs [18]. Several studies reported an increased disease-
free survival with no significant impact on overall survival,
raising the question as to whether lymph node dissection is
necessary in the case of a positive SLNB. In a recent study,
CLND reduced subsequent regional lymph node meta-
stases and improved disease-free survival, while overall
survival remained unaffected [19]. Sixty-seven to 90% of
SLN-positive patients do not have further non-SLNs that
contain tumour deposits in the CLND specimens [20]. As
a consequence, the majority (80%) of SLN-positive pa-
tients undergo unnecessary surgery associated with con-
siderable morbidity. Therefore, several authors have tried
to identify patient, tumour and SLN characteristics pre-
dicting further non-SLN positivity to safely avoid CLND
[20]. Although previous studies have failed to identify the
same clinicopathological features as indicators for addi-
tional non-SLN positivity upon CLND or for disease-free
survival [21], SLN tumour load, nevertheless, was uni-
formly confirmed by all of these studies as prognosticator
for non-SLN positivity and recurrence. In addition, the im-
pact of SLN tumour burden on disease-free and overall sur-
vival was demonstrated in several studies [20]. CLND has
not yet been proven to improve overall melanoma-specif-
ic survival. However, Cascinelli et al. [22] have shown that
CLND is necessary to achieve the best assessment of pro-
gnosis of stage IB and II melanoma and to identify those
patients who, having only positive sentinel nodes and neg-
ative non-sentinel nodes, have a good prognosis. There is
considerable debate as to how to stratify SLN tumour bur-
den; Satzger et al. [23] found that isolated tumour cells are
without prognostic significance and disease-free survival
of these patients did not differ from that of SLN-negative
patients, an observation that is supported in a broader sense
by Van Akkooi et al. [24]. In their study, no patient with an
SLN tumour load of <0.1 mm had additional non-SLN pos-
itivity upon CLND, and 5-year overall survival was 100%.
On the basis of these data, the UICC classifies SLNs with
isolated tumour cells as negative (pN0 (i+), in contrast to
the AJCC, who define every melanoma cell, even if single,
as a metastasis (pN1a). There is currently no consensus
among eminent guidelines [12, 25] as to whether isolated
tumour cells should be considered as metastases and the
patient consequently undergo CLND or not. Therefore, we
do not recommend complete lymph node dissection in pa-
tients who present only isolated tumour cells in their sen-
tinel node until the presence of this pathological feature
has shown clear prognostic implications. Discrepancies ex-
ist in particular in the role of the SLN tumour burden and
on the value of ultrasound-guided follow-up, a method that
can detect early recurrences in the regional nodal basin
and prompt a CLND only in patients with such eviden-
ce. Based on these differing expert opinions, the benefits
and shortcomings of CLND should be discussed carefully
with patients having SLN with isolated tumour cells and
stage N1a with low tumour load, until the currently ongo-
ing Multicenter Selective Lymphadenectomy Trial II has
clarified these issues. Recurrences in the regional nodal
bases, irrespective of whether it was previously staged or
not, mandate lymph node dissection [26]. However, before
undertaking additional aggressive local surgical treatments,
a detailed staging investigation, including imaging tech-
niques such as CT or PET, is necessary to exclude the pres-
ence of further metastases.
Adjuvant therapy
Many clinical trials have investigated the impact of ad-
juvant treatment modalities in high-risk melanoma.
However, solid evidence can be gleaned only from pro-
spective randomised multicentre trials. Neither ELND, per-
fusion of the extremities, radiotherapy or chemotherapy
have been able to produce a significant increase in the
length of survival rate benefit to the melanoma patient col-
lective as a whole [27]. Adjuvant treatment with Viscum al-
bum (Iscador®) is not recommended, since it might acceler-
ate the disease course [28]. A large international trial using
pegylated interferon has demonstrated a positive effect on
disease-free and overall survival in patients with micro-
metastases and an ulcerated primary tumour (pTxb, N1a)
[29, 30]. In this patient population interferon can be recom-
mended, if the individual patient tolerates it well (level of
evidence III). Adjuvant treatment in patients with resected
macroscopic involvement (N1b) should only be applied in
the context of clinical trials in specialised centres.
Many new adjuvant trials including checkpoint inhibitors
trials, are under development for patients with stage III dis-
ease and could soon extend to stage IIB and IIC patients
(some of whom having a higher risk of developing meta-
static disease than a subgroup of stage IIIA patients). We
therefore recommend that, irrespective of their staging, all
these patients should be referred to specialised centres in
order to give them the chance of being enrolled in adjuvant
therapy trials.
Radiotherapy for local tumour control should be con-
sidered in cases of inadequate resection margins of lentigo
maligna melanoma [11] or R1 resections of melanoma
metastases when surgery is not adaquate (III, B). A pro-
spective randomised trial has demonstrated that postoperat-
ive irradiation after lymph node dissection reduces the risk
for relapse in the irradiation field by approximately 50%,
but has no impact on relapse-free and overall survival [31].
Local therapy of distant metastasis
In the case of regional disease, surgery or radiotherapy may
be an effective palliative treatment option, if it is technic-
ally feasible, if risk of morbidity and mortality is low and
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if the patient is likely to live long enough to derive a be-
nefit. A PET-CT scan should be performed before any loc-
al treatment to exclude further lesions. Good examples for
palliative surgery or radiotherapy are single lesions local-
ised to the brain, bowel, liver and lung or spinal cord. In
some patients a long survival time after complete resection
has been described [32–35].
Radiotherapy
Radiotherapy plays an important role in achieving local
control and palliation of many symptoms in melanoma pa-
tients, especially for symptomatic brain metastases, pain-
ful bone, lymph node and soft tissue metastases, as well as
nerve compression symptoms. For extracranial metastases,
irradiation with larger single-fraction doses is preferred and
total doses should be adjusted to the patient’s life expect-
ancy. Overall, good palliation can be obtained in two thirds
of the cases. Whereas whole brain irradiation is still the
standard treatment for patients with multiple brain meta-
stases and patients with short life expectancy because of
progressive extracranial disease, stereotactic radiotherapy
or radiosurgery alone without whole brain irradiation has
become the standard for patients with a limited number of
melanoma brain metastases [36].
Whereas radiotherapy alone or in combination with chemo-
therapy is well established, the combination with targeted
drugs is an area of particular interest and data about poten-
tial interactions between radiotherapy and systemic treat-
ment are still not mature. In patients with melanoma brain
metastases, concurrent administration of ipilimumab and
stereotactic radiosurgery or short-course fractionated ste-
reotactic radiotherapy was safe [37, 38].
Administration of ipilimumab during or after radiotherapy
may be beneficial in terms of overall survival and regional
recurrence [39], but whether timing and sequencing of ra-
diotherapy and ipilimumab influence toxicity and efficacy
remains unclear The safety of combining radiotherapy in
general or radiosurgery for brain metastases with inhibitors
of B-RAF (serine/threonine-protein kinase B-RAF) is re-
ported controversially in the literature and no data from
prospective trials are available. Whereas some studies re-
ported B-RAF inhibitors as radiosensitisers [40, 41] with
the potential consequence of increased or severe toxicity,
especially radiation recall dermatitis [33, 42], this was not
confirmed by other studies [43, 44]. Nevertheless, it is gen-
erally recommended to stop B-Raf inhibitors during whole
brain irradiation, but not stereotactic therapy; however,
data confirming this practice are rare or even conflicting
[37, 45].
Systemic treatment of metastatic melanoma
Since a few years ago, there is exciting progress in treat-
ment of advanced recurrent and metastatic melanoma [46].
Guidelines can hardly keep up with standard practice-chan-
ging data presented and published. Nevertheless we believe
that patients should be referred to interdisciplinary skin
cancer centres that offer well-designed clinical trials
whenever possible. Genetic testing for potential driver
mutations with the prospect of treatments with targeted
agents and small molecules such as B-Raf inhibitors, MEK
inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors and
others are strongly recommended. The individual muta-
tions profile is essential for treatment decisions.
Testing for BRAF mutation in exon 15 is required. In
BRAF wild-type tumours N-RAS mutation testing in exons
1 and 2 should be considered. Both mutations are over-
whelmingly mutually exclusive. N-RAS testing should be
performed if participation in a clinical trial or a treatment
with a MEK inhibitor in further treatment lines is planned.
Testing for c-KIT mutation should be performed in acrolen-
tiginous and mucosal melanoma in prospect of a clinical
trial or treatment with a c-KIT inhibitor in the course of dis-
ease.
Unfortunately, clinical trials are not available for all melan-
oma patients. In this situation and in B-RAF, N-RAS, and
c-KIT wildtype patients, systemic treatments with modern
immunomodulatory checkpoint inhibitors are recommen-
ded (I, A). Classic chemotherapy agents, commonly used
during past decades, have lost their importance in this dis-
ease.
The effectiveness of immunomodulatory agents is inde-
pendent of the underlying genetic profile (before men-
tioned mutations) and no clinically useful predictive mark-
ers have been validated so far. This fact, together with the
characteristic response patterns of delayed and long-last-
ing responses, renders the sequence of treatments, whether
with small molecules or immunotherapy, one of the most
important challenges for treating physicians.
Treatment sequence should be tailored to the patient and
the individual medical needs (patient characteristics, tu-
mour load, tumour dynamics, metastatic pattern, genetic
profile). Treatment choice and sequence depends also on
the local access to new agents through compassionate use
or early access programmes and the approval status of
agents considered by the Swiss regulatory authority.
Immunomodulatory agents (checkpoint-inhibitors)
The anti-CTLA4 (cytotoxic T lymphocyte-associated anti-
gen-4) antibody ipilimumab was shown to prolong overall
survival in first- and second- line therapy of stage IV
melanoma [47, 48]. Despite the considerable side effects,
this treatment option is considered to be a reasonable first-
or second-line therapy. Even in patients with naïve or pre-
treated brain metastasis, often underrepresented in large
phase III trials, clinical benefit was demonstrated in phase
II trials [Schadendorf JCO 2015]. This treatment should
only be offered in specialised centres experienced in apply-
ing immunotherapies and in the treatment of related toxicit-
ies. It is recommended that the treating centres join nation-
al and international research programmes to contribute to
a better understanding and definition of the patient popula-
tion that profits from this therapy.
Anti-PD1 (programmed death-1) antibodies (pembrolizu-
mab, nivolumab) show impressive results as first- and fur-
ther line treatments, with impressive long-lasting responses
and very promising survival rates [49, 50]. The toxicity
profile is more favourable than chemotherapy or ipilimu-
mab with few grade 3 and 4 adverse reactions [49, 51]. Pa-
tients should be seriously considered for these agents with-
in or outside of clinical trials.
The combination of ipilimumab and nivolumab shows
promising response rates and progression-free survival in
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comparison with monotherapy, but its toxicity is significant
[52]. Its impact on overall survival is not yet available and,
therefore, it remains unclear if it is preferable to anti-PD1
monotherapy.
Targeted therapy against driver mutations (B-Raf and
others)
Selective B-RAF inhibitors (dabrafenib, vemurafenib)
have demonstrated high response rates and improved sur-
vival in comparison with chemotherapy in phase III trials
for patients with BRAF mutations (40% of melanoma pa-
tients) [53, 54]. Furthermore, combination treatments with
B-RAF and MEK (mitogen-activated extracellular signal
regulated kinase) inhibitors (dabrafenib with trametinib,
vemurafenib with cobimetinib) improved response rates
and survival, even lowering the incidence of specific tox-
icities (e.g. secondary skin tumours) in comparison with
monotherapy [55–57].
In patients with BRAF-mutated symptomatic melanoma
(pain, B symptoms, bulky disease) a B-RAF/MEK inhibit-
or combination represents a preferred therapy. There is no
head-to-head comparison of this treatment with anti-PD1
therapy. The authors suggest the following aspects to apply
to support first-line treatment with a B-Raf/MEK inhibitor
combination:
– Patients with a symptomatic high tumour burden
– Patients with brain metastases, especially if
progressively symptomatic and if steroid treatment is
needed
– Elevated lactate dehydrogenase levels, at least twice the
upper limit of the reference range
– Patients with inflammatory syndrome with a shift in
blood counts, neutropenia, and elevated C-reactive
protein levels
– Evidence of bone marrow involvement
– Pre-existing autoimmune disease (rheumatoid arthritis,
inflammatory bowel disease [Crohn’s disease],
Wegener’s disease)
If clinical judgment, considering the criteria listed, sug-
gests other therapies first, anti-PD1 immunotherapy should
be considered as front-line treatment.
In patients with brain metastasis, promising intracranial ef-
ficacy has been demonstrated with B-Raf inhibitors [58,
59]. These new data established treatment algorithms and
treatment modalities for patients with asymptomatic brain
metastasis that suggest first-line palliative irradiation. Ste-
reotactic irradiation can be safely combined with kinase in-
hibitors and is preferred to whole brain irradiation whenev-
er feasible.
N-RAS-mutated melanomas should be considered for
MEK inhibitor therapy in the course of treatment and c-
KIT-mutated tumours for treatment with tyrosinase kinase
inhibitors despite the lower level of evidence and related
studies on their way [60, 61].
Cytotoxic chemotherapy
With the emergence of novel targeted and immunother-
apies, classic chemotherapy is losing its importance in this
disease, as already mentioned. Nevertheless, in highly pro-
liferating disease or as salvage treatment, chemotherapy
can still be considered.
Dacarbazine (DTIC) is one of the most used substances
in metastatic melanoma and is still the reference treatment
in many countries. Temozolomide demonstrated efficacy
equal to that of dacarbazine, but offers better penetration
into the central nervous system. Treatment with bisphos-
phonates or denosumab should be considered in patients
with bone metastases to avoid skeletal-related events and
bone pain.
In aggressive symptomatic disease, polychemotherapy in-
cluding cisplatin, vindesine and dacarbazine as first-line
treatment (response rate: 40%) [62] or the combination of
carboplatin and paclitaxel as second-line [63] produced a
partial response in 11% and disease stabilisation in 51% of
the patients. However, an impact on disease-free or overall
survival was not shown in either study.
Biochemotherapy, a combination of interleukin-2 and/or
interferon-alpha with chemotherapeutic agents such as da-
carbazine, temozolomide, fotemustine, cisplatin, carboplat-
in, vinblastine, paclitaxel or docetaxel demonstrated higher
response rates but this was not translated into a better sur-
vival than that with a single agent, and has been associated
whether an increase in toxicity [64, 65]. It is not recom-
mended. There are no randomised clinical trials of inter-
leukin-2 monotherapy. Some centres still use this therapy
in well-selected patients with low tumour burden, despite
the lack of convincing phase III data.
Anti-vascular endothelial growth factor antibodies have
shown some activity in phase II trials but no positive phase
III studies have been reported so far [66, 67].
To conclude, all stage IV melanoma patients need to be
referred to reference centres with broad experience in the
management of this disease, discussed by an interdiscip-
linary melanoma tumour board and should preferably be
treated in well-designed clinical trials. Recommended
treatment strategies for metastatic melanoma are summar-
ised in table 3.
Follow-up
The patient should be instructed in avoidance of sunburn,
extended unprotected solar or artificial ultraviolet exposure
and in lifelong regular self-examination of the skin and
peripheral lymph nodes. The patient must be aware that his
or her family members have an increased melanoma risk.
The aim of melanoma follow-up is to detect a relapse or
an additional skin tumour as early as possible. The risk of
developing a second melanoma is 5–8% within the first 2
years after diagnosis. Thirty-five percent of patients with
lentigo maligna melanoma develop another malignant tu-
mour of the skin during the next 5 years [11]. Although
the hypothesis suggesting that regular monitoring reveals
early detection of metastasis may be well founded, no ran-
domised studies have demonstrated that early detection of
metastases improves the overall survival [68].
The follow up schedule is based mainly on dated literature
and historical practice [69] (level of evidence IV). Despite
numerous attempts to achieve international consensus on
follow-up guidelines, there is no universal valid agreement.
However, locoregional lymph node metastases are the most
common event in patients that are regularly checked.
Therefore, it is worthwhile to focus on cutaneous relapses
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and locoregional lymph nodes. Physical examination re-
mains the mainstay of follow-up visits. In addition, patients
should be trained in self-examination, because most re-
lapses have been detected by themselves. This fact raises
the question whether routinely performed clinical examin-
ations and imaging procedures, based on the relapse risk
over time, generate a real benefit for melanoma patients
[27]. Probably false positive results could be reduced by in-
creasing the time between visits and would anyhow be suf-
ficient for psychological support [27].
The first 5 years after diagnosis are the most important,
as 90% of all metastases occur during this period, and so
clinical examinations and imaging procedures have to be
more frequent for the first 5 years. Because melanoma is
a tumour that can have late metastasis, lifelong surveil-
lance beyond 10 years is generally recommended [70]. Th-
in melanomas with a Breslow depth less than 1 mm have
only a small risk of relapse and thus need no imaging. Be-
cause sonography is easy to perform, cheap, not harmful
and more sensitive than clinical examination in revealing
lymph node metastasis, it should be routinely done. Table
4 presents the suggested time schedule of examinations for
Switzerland. To detect further metastasis in stage III (and
in stage IIC because of its similar prognosis) an imaging
study of the whole body, preferably with PET-CT, is recom-
mended [71]. S-100 protein is a good marker for melan-
oma relapse, especially for predicting disease-free survival
in stage III melanomas [72, 73]. In stage IV melanomas in-
tervals between check-ups have to be individually adjusted
according the therapeutic intentions.
Disclosure statement: Prof. Dummer receives research
funding from Novartis, Merck Sharp & Dhome (MSD), Bristol-
Myers Squibb (BMS), Roche, GlaxoSmithKline (GSK) and has
a consultant or advisory board relationship with Novartis, Merck
Sharp & Dhome, Bristol-Myers Squibb, Roche,
GlaxoSmithKline, Amgen, outside the submitted work.
Table 3: Recommended treatment strategies for metastatic melanoma.
Number and localisation of the metastases Treatment modalities
1. 1st choice
2. 2nd choice
3. 3rd choice
In-transit metastases (few) (pTXN2cM0) 1. Surgical removal
2. Radiotherapy
In-transit metastases (multiple, >5) (pTXN2cM0) 1. Perfusion of the extremity*
2. Radiotherapy
3. Electrochemotherapy
4. T Vec gene therapy
3. Targeted / immunotherapy*
Locoregional lymph nodes (pTxN1a,2a) 1. Consider trial participation
2. Additional Interferon-alpha treatment*
Locoregional lymph nodes (pTxN2b,2c,3) 1. Radical lymphadenectomy, in the event of incomplete resection or
proven risk factors: Radiotherapy
2. Consider trial participation
Solitary central nervous system metastasis (pTxNxM3) 1. Neurosurgical removal
2. Radiosurgery or stereotactic irradiation* (according to localisation this
could also be the 1st choice)
Solitary lung metastasis (pTxNxM1) 1. Surgical removal
2. Stereotactic irradiation (SBRT) (according to localisation this could
also be the 1st choice)
3. Consider clinical trial participation
4. Targeted / immunotherapy*
Multiple metastases (pTxNxM1a-1c) 1. Consider clinical trial participation
2. Radiosurgery or stereotactic irradiation with up to 5 metastases
3. Targeted/immunotherapy*
Painful bone metastases (pTxNxM1a-1c) 1. Consider clinical trial participation
2. Bone-specific therapy (e.g., bisphosphonates, denosumab)
3. Radiotherapy (SBRT)
4. targeted/immunotherapy*
SBRT = stereotactic body radiation therapy
* These therapies should be restricted to controlled studies at specialised centres.
Table 4: Follow-up intervals (months).
Stage
(TNM)
Physical
examination
years 1–3
Physical
examination
years 4–5
Physical
examination
years 6–10
Locoregional lymph
node sonography
years 1–5
S-100
years 1–5
Abdominal
sonography and
chest x-ray
years 1–5
CT, MRI, PET
or PET-CT
years 1–5
I (≤T1N0) 6–12 12 12 – – – –
I (T2N0), IIA+B 3 6 6–12 6–12 6–12 Individual –
IIC, III 3 3 6 6 6 Individual 6–12
IV Individual Individual Individual Individual Individual Individual Individual
CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography
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